BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 8946039)

  • 1. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
    Hohenberger P; Bida B; Schlag PM
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
    [No Abstract]   [Full Text] [Related]  

  • 2. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
    Haier J; Hohenberger P; Beck K; Schlag PM
    Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom.
    Hill S; Thomas JM
    Melanoma Res; 1994 Mar; 4 Suppl 1():31-4. PubMed ID: 8038593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Isolated extremity perfusion with TNF-alpha and melphalan in unresectable soft tissue sarcoma. Indications, principles and technique].
    Taeger G; Ruchholtz S; Niebel W; Müller S; Nast-Kolb D
    Unfallchirurg; 2004 Jul; 107(7):619-23. PubMed ID: 15252711
    [No Abstract]   [Full Text] [Related]  

  • 9. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
    Lejeune FJ; Eggermont AM
    J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
    Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
    Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
    Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
    Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma.
    Jakob J; von Rege I; Weiss C; Hohenberger P
    Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
    Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
    Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.